LMAT logo

LEMAITRE VASCULAR INC

LMATNASDAQ
πŸ† #1805 by market capEarnings Nov 5US Equity
$80.85β–Ό $1.94 (βˆ’2.40%)
Live
1hβ–Ό 0.7%
24hβ–Ό 2.4%
7dβ–² 2.5%
14dβ–Ό 22.0%
30dβ–Ό 19.3%
1yβ–Ό 13.7%
🏦Market Cap
$1.85B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+11.8%
Healthy
πŸ“ŠGross Margin
72.9%
High
πŸ’΅FCF Margin
28.1%
Strong
βš–οΈP/S Ratio
7.2x
Fair
Otter Score
46
Weak

Trading Snapshot

Day Range
$80.12 – $81.83
52-Week Range
$78.65 – $118.01
Volume
$1.79B
Avg Volume
$1.83B
Shares Outstanding
22.9M
Next Earnings
Oct 16, 2026

Fundamentals Snapshot

Annual Revenue
$250M
Last Q Revenue
$70M
P/E Ratio
28.6
P/S Ratio
7.2x
EPS (TTM)
$2.77
Dividend Yield
1.09%

Why Investors Own LMAT

  • βœ“High-growth profile β€” revenue up +20.9% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 71% gross margin and 30% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$250Mβ–² +17.0% YoY
Gross Margin (TTM)
71.0%β–² +4.0% YoY
Operating Income (TTM)
$31Mβ–² +17.0% YoY
Free Cash Flow (TTM)
$74Mβ–² +17.0% YoY

About LEMAITRE VASCULAR INC

Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
46/100

Analyst Price Target

β“˜
Average Target
$106.78
β–² +32.1% Upside
High Target$116.05
Low Target$97.98
Based on 22 analysts

Latest News & Updates